According to Zion Market Research, the global Parkinson’s disease treatment market is anticipated to attain USD 8.38 billion by the end of 2026, developing at a CAGR of over 7.5% during the forecast period 2020–2026. The increasing geriatric population along with neurological disorders, surging investments in research & development operations, and augmenting healthcare awareness are some of the aspects impelling the market growth over the estimated period. The surging incidence of Parkinson’s disease is likely to accelerate the development of this industry in the future. The global market is projected to register considerable growth over the forecast period. Nevertheless, the availability of other treatments is impacting market expansion.
Some of the key players in the global market are Novartis AG; GlaxoSmithKline Plc.; Impax Laboratories, Inc.; Teva Pharmaceutical Industries Ltd.; BIAL Pharm; Par Pharmaceutical; Orion Corporation; Daiichi Sankyo; Mylan N.V.; Wockhardt Limited; Cipla Inc.; Salix Pharmaceuticals; and Apotex Inc.
Request Free Sample is Available @ https://www.zionmarketresearch.com/sample/parkinsons-disease-treatment-market
New Innovations In Therapeutics Will Stimulate The Growth Of Global Parkinson’s Disease Treatment Market
The latest advancements in Parkinson’s disease therapeutics like combination therapies to delay the action of constant dopaminergic stimulation drugs, authorization for neurostimulation devices, neuroprotective treatments to slow down a prediction of disease, neural transplantation, gene therapy, etc. are projected to bring huge growth in the global Parkinson’s disease therapeutics market during the forecasted period. Furthermore, augmenting geriatric population, occurrence of Parkinsonism globally are the factors boosting the demand for Parkinson’s disease therapeutics. But generic erosion owing to patents expiration for many drugs like Stalevo (2012), Rytary, Comtan (exclusivity expired in 2013), Azilect (2017), etc. would dissuade the expansion of the global market.
The global Parkinson’s disease treatment market is bifurcated on the basis of therapeutic class, medical devices, patient care setting, distribution channel, and regional analysis. Based on therapeutic class, the market is divided into dopamine precursors, monoamine oxidase B inhibitors (MAO-B inhibitors), catechol-O-methyl transferase (COMT) inhibitors, carbidopa/levodopa, dopamine agonists (non-ergoline), and other therapeutic classes. Based on the medical devices, the market is divided into deep brain stimulation (DBS) devices and carbidopa/levodopa enteral suspension (Duopa) delivery devices. Based on the patient care setting, the market is divided into clinics and hospitals. Based on the distribution channel, the market is divided into online pharmacies, retail pharmacies, drug stores, and hospital pharmacies.
Asia Pacific Region Will Register Highest CAGR In The Global Parkinson’s Disease Treatment Market
Based on geographical analysis, the global Parkinson’s disease treatment market is divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The Parkinson’s disease treatment market is ruled by Europe, accompanied by North America, nonetheless, the Asia Pacific region is likely to register the highest growth over the forecasted period. Asia Pacific is anticipated to register the highest CAGR, with the development in this market centered in China, Japan, and India. The surging number of generic drug producers and the increasing aging population across the region are key aspects driving the market.
To view TOC of this report is available upon request @ https://www.zionmarketresearch.com/toc/parkinsons-disease-treatment-market
The global Parkinson’s disease treatment market is segmented as follows:
By therapeutic class:
- Dopamine precursors
- Monoamine oxidase B inhibitors (MAO-B inhibitors)
- Catechol-O-methyl transferase (COMT) inhibitors
- Dopamine agonists (non-ergoline)
- Carbidopa/Levodopa
- Other Therapeutic Classes
By medical devices:
- Deep Brain Stimulation (DBS) Devices
- Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices
By patient care setting:
- Clinics
- Hospitals
By distribution channel:
- Online pharmacies
- Retail pharmacies
- Hospital pharmacies
- Drug stores
By region:
- North America
- The U.S.
- Canada
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Browse the full Report at https://www.zionmarketresearch.com/report/parkinsons-disease-treatment-market
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com
